NOF CORPORATION has announced that they have entered into a non-exclusive agreement with Enzon Pharmaceuticals, Inc., a world-wide biopharmaceutical company in PEGylated drug development, for global sales of Enzon’s proprietary PEG-linkers. The licensed patent estate includes at least 28 PEG derivatives.
The agreement enables NOF to provide a global supply of Enzon’s original PEG reagents, including Branched PEG and Releasable PEG. NOF will manufacture those PEGs from reagent to clinical stage in a state of the art cGMP facility. Enzon will receive a license fee on actual product sales, as well as exchange contracts with NOF’s clients prior to commercial sales.
In addition to current PEG reagents, NOF product line-up can be greatly expanded in the background of proprietary technology and know-how of Enzon.
Hereafter, as a diversified PEG derivative supplier, NOF will launch new products on our catalog and promote them to pharmaceutical companies through out the world.
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of important medicines for patients with cancer and other life-threatening conditions. The Company’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon’s PEGylation technology has created a royalty revenue stream from licensing partnerships for other products developed using the technology. For further information about Enzon please visit the Company’s web site at www.enzon.com.
